Biogen Idec Plans Jump to Phase 3 Trial for Alzheimer’s Drug Based on Early-Stage Data

Biogen Idec Plans Jump to Phase 3 Trial for Alzheimer’s Drug Based on Early-Stage Data
Biogen Idec, the company behind several of today's most widely sold multiple sclerosis drugs, has been developing a novel treatment for Alzheimer's disease, called BIIB037, which has shown great potential in blocking beta amyloid -- one of the hallmarks of this common form of dementia -- and improving
Subscribe or to access all post and page content.